Avidin has developed a novel blood based diagnostic test that measures acquired T-cell immunity against the SARS-CoV2 coronavirus, following infection or immunization. Avidin is the first private company to offer such a test in Hungary.
Avidin’s Budapest site (Berlini u 47-49) was accredited as M3 authorization level of microbiological diagnostics laboratory.
The aim of the project was the acquisition of the Advia Centaur® XPT immunochemical automate system manufactured by Siemens, followed by the adaptation of the test assays provided by the instrument.
New patent application of anti-cancer drug candidate.
Avidin can simultaneously check for Covid-19 and Influenza infection from the same specimen by using its multi-diagnostic PCR solution with high specificity and sensitivity.
Avidin, led by Dr. Liliana Fehér, has developed its own one-step RT-PCR kit, the Cov2QuantTM SARS-Cov-2 Quantification kit (cat: CQ-100), designed to detect the novel corona virus, SARS-Cov-2, quantitatively by using reverse trascription reaction and quantitative real-time polymerase chain reaction.
Avidin has expanded the company’s portfolio with a specialized clinical molecular diagnostics department focused on the detection and monitoring of infectious diseases.
Avidin set up viral diagnostics lab and developed own reagents and method to combat Covid-19 reported by HVG 05/28/2020 Avidin, reported by HVG (Weekly World